{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pen+auto-injector", "query": { "intervention": "Pen auto-injector" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pen+auto-injector&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T13:43:24.557Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02683746", "title": "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lyophilized albiglutide DCC pen injector", "type": "DRUG" }, { "name": "Lyophilized albiglutide DCC pen injector matching placebo", "type": "DRUG" }, { "name": "Albiglutide liquid auto-injector", "type": "DRUG" }, { "name": "Albiglutide liquid auto-injector matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 308, "start_date": "2016-03-16", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02683746" }, { "nct_id": "NCT00688701", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2008-05", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-12-12", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688701" }, { "nct_id": "NCT03439072", "title": "G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Insulin Hypoglycemia", "Type 1 Diabetes Mellitus", "Severe Hypoglycemia" ], "interventions": [ { "name": "G-Pen", "type": "DRUG" }, { "name": "Lilly Glucagon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xeris Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 81, "start_date": "2018-01-23", "completion_date": "2018-05-03", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 4, "location_summary": "Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439072" }, { "nct_id": "NCT00335855", "title": "Pharma-Pen (Formerly Innoject) Auto-injectory TIV", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Auto-injector for IM/SC vaccine administration", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335855" }, { "nct_id": "NCT00707031", "title": "GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Exenatide", "type": "DRUG" }, { "name": "Prefilled pen injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 639, "start_date": "2008-06", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-12-02", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707031" }, { "nct_id": "NCT00763815", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 484, "start_date": "2008-09", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00763815" }, { "nct_id": "NCT02660736", "title": "Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Albiglutide Liquid Auto-injector", "type": "DRUG" }, { "name": "Albiglutide Lyophilized DCC Pen Injector", "type": "DRUG" }, { "name": "Placebo Liquid Auto-injector", "type": "DRUG" }, { "name": "Placebo Lyophilized DCC Pen injector", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 59, "start_date": "2016-02", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-11-09", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02660736" }, { "nct_id": "NCT02023879", "title": "Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for Alirocumab)", "type": "DRUG" }, { "name": "Non-statin LMT", "type": "DRUG" }, { "name": "Diet Alone", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2013-12-16", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2018-07-27", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 8, "location_summary": "Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Fall River", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023879" }, { "nct_id": "NCT01644175", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644175" }, { "nct_id": "NCT00715624", "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Basal Insulin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2008-07", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-09-03T13:43:24.557Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715624" } ] }